SHP-2 antibody | knockout validation | Cell Signaling 3397

This is a knockout-validated antibody summary, based on the publication "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: SHP-2

Catalog number: 3397

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to the carboxy-terminal sequence of human SHP-2. Reacts with human, mouse, rat, and monkey. Suitable for western blot, immunoprecipitation and immunohistochemistry (paraffin).

Validation Method

Immunohistochemistry

Sample

Control and Kras;Ptpn11-/- mice pancreas. Tissues were formalin-fixed and paraffin-embedded for sectioning.

Primary incubation

1:200 dilution.

Detection

Avidin–biotin enhancement (Vector Laboratories) and developing with DAB (3,3'-diaminobenzidine, Vector Laboratories). Image acquisition was achieved on a Zeiss AxioImager.A1 microscope.

Figure

SHP2 is expressed in the epithelial compartment during KrasG12D-driven pancreatic carcinogenesis in mice. Immunohistochemical analysis of pancreatic tissue sections from Kras mice for SHP2. Top left: normal acinar tissue, bottom left: PanIN precursor lesions, top right: PDAC, bottom right: liver metastasis. Inset: normal acinar tissue from Kras;Ptpn11-/- mice served as control. Scale bars: 100 µm. Experiment performed on six different Kras PDAC mice, with similar results. Please see Suppl. Figure 2a in the article [1].

References
  1. Ruess D, Heynen G, Ciecielski K, Ai J, Berninger A, Kabacaoglu D, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat Med. 2018;24:954-960 pubmed publisher